Stock Quote RO - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

Bid

Ask

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Previous Close

Open

Last Trade

Last Trade Time

Average Volume (3m)

Financial Volume

VWAP

Pivotal Phase II Study Showed Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People With a Specifi...

-- Genentech will discuss results with the U.S. Food and Drug Administration (FDA) as part of atezolizumab’s Breakthrough Therapy Designation in lung cancer -- Genentech, a member of the...

Pivotal Phase II Study of Investigational Medicine Venetoclax Met Primary Endpoint in a Hard-to-Treat Type of Chronic Lymphoc...

-- Regulatory applications for venetoclax are planned for submission to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) by the end of 2015...

In a Pivotal Study, Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People With a Specific Type of ...

-- Results showed that high levels of PD-L1 expression were associated with greater responses to atezolizumab -- -- Genentech will discuss results with the U.S. Food and Drug...

Genentech’s ocrelizumab Significantly Reduced Both Relapses & Disability Progression versus interferon beta-1a (Rebif®) in...

Studies showed superiority on primary and major secondary endpoints in people with relapsing forms of multiple sclerosis Genentech will submit data to the U.S. Food and Drug...

FDA Grants Breakthrough Therapy Designation for Actemra (tocilizumab) in Systemic Sclerosis

Systemic sclerosis affects approximately 75,000 to 100,000 people in the U.S. and has highest mortality rate of any autoimmune rheumatic disease1,2 There is no FDA-approved therapy...

Genentech’s Perjeta Regimen Helped People with HER2-positive Early Breast Cancer Live Longer without Their Disease Returnin...

-- New data from Phase II NeoSphere study provide additional evidence on the role of Perjeta in the neoadjuvant (pre-surgery) treatment of HER2-positive early breast cancer -- Genentech...

Genentech’s Gazyva® Extended the Time People With Refractory Indolent Non-Hodgkin’s Lymphoma Lived Without Their Disease...

-- GADOLIN is the second positive Phase III study in the Gazyva clinical development program -- -- Genentech and Roche will submit data from the GADOLIN study to regulatory authorities...

Genentech’s Investigational Medicine Alectinib Shrank Tumors in Nearly Half of People With Specific Type of Lung Cancer

-- Alectinib showed response rates of up to 69 percent in the central nervous system (CNS) in people with advanced ALK-positive non-small cell lung cancer -- -- Genentech plans to...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
SKPStrikepoint Gold Inc	$ 0.30 (900.00%)	50.57k
NLII.PNL2 Capital Inc	$ 0.15 (150.00%)	22k
ETUE2gold Inc	$ 0.01 (100.00%)	160.79k
LSD.HLightspeed Discoveries Inc	$ 0.05 (100.00%)	3k
DMDataMetrex AI Limited	$ 0.01 (100.00%)	121.47k
PPMPacific Imperial Mines Inc	$ 0.005 (-66.67%)	216k
GAR.HGreen Arrow Resources Inc	$ 0.01 (-60.00%)	2.5k
RUN.HRunning Fox Resource Corp	$ 0.005 (-50.00%)	2k
CBAChampion Bear Resources Ltd	$ 0.045 (-43.75%)	61.17k
XNDXander Resources Inc	$ 0.03 (-33.33%)	1.25M
WRLGWest Red Lake Gold Mines Ltd	$ 0.69 (-6.76%)	4.77M
AECAnfield Energy Inc	$ 0.135 (3.85%)	3.23M
VMCVicinity Motor Corp	$ 0.065 (-23.53%)	3.21M
HELIFirst Helium Inc	$ 0.045 (-10.00%)	3.04M
ECRCartier Resources Inc	$ 0.10 (17.65%)	2.86M